Why the study?
Cardiotoxicity related to 5-FU causes significant morbidity and mortality, creating a clinical dilemma regarding whether patients with major cardiac side effects can be safely rechallenged.
Can a patient with prior 5-FU-induced ventricular fibrillation be safely rechallenged with 5-FU using prophylactic antianginal therapy?
Comparison
5-FU/leucovorin rechallenge with prophylactic antianginal pre-treatment
Design
Case report
Authors
Loading...
May inform individualized 5-FU rechallenge decisions with prophylaxis; hypothesis-generating and requires prospective trials before practice change.
Can a patient with prior 5-FU-induced ventricular fibrillation be safely rechallenged with 5-FU using prophylactic antianginal therapy?
5-FU rechallenge may be feasible even after severe cardiotoxicity (ventricular fibrillation) when utilizing a multidisciplinary approach and prophylactic antianginal therapy.
Desai et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: